Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Bennicelli

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2010
Chemotherapy: which drug and when?A Sobrero, E Bennicelli
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 13, 2007
First-line single-agent cetuximab in patients with advanced colorectal cancerA Pessino, S Artale, S Sciallero, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 22, 2010
Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapiesS Mammoliti, V Andretta, E Bennicelli, et al.
British Journal of Cancer|July 2, 2009
Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumoursV Gregorc, A Santoro, E Bennicelli, et al.
ESMO Open|March 16, 2024
REGOMA-OSS: a large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastomaM Caccese, I Desideri, V Villani, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2010
Chemotherapy: which drug and when?A Sobrero, E Bennicelli
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 13, 2007
First-line single-agent cetuximab in patients with advanced colorectal cancerA Pessino, S Artale, S Sciallero, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 22, 2010
Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapiesS Mammoliti, V Andretta, E Bennicelli, et al.
British Journal of Cancer|July 2, 2009
Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumoursV Gregorc, A Santoro, E Bennicelli, et al.
ESMO Open|March 16, 2024
REGOMA-OSS: a large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastomaM Caccese, I Desideri, V Villani, et al.
Pageof 1